表柔比星联合紫杉醇治疗乳腺癌疗效及其对患者血清抵抗素、脂联素水平的影响研究

Treatment efficacy of epirubicin combined with paclitaxel on breast cancer and its effect of serum resistin and adiponectin levels

目的探讨表柔比星联合紫杉醇治疗乳腺癌疗效及其对患者血清抵抗素、脂联素水平的影响。方法将2013年1月-2016年1月入住本院的96例经病理及影像学诊断确诊的乳腺癌患者按照1∶1的比例随机分为对照组与观察组。对照组仅采用紫杉醇治疗,观察组在此基础上联合表柔比星治疗。比较两组疗效及血清抵抗素、脂联素水平。结果观察组临床控制总有效率及临床收益率均显著高于对照组,差异有统计学意义(P<0.05);观察组患者治疗半年及1年时的子宫内膜厚度均显著小于对照组相对应时间节点水平,差异有统计学意义(P<0.05);两组患者治疗后血清抵抗素水平均显著低于治疗前,血清脂联素水平均显著高于治疗前,差异有统计学意义(P<0.05)。结论表柔比星联合紫杉醇治疗乳腺癌疗效显著,可有效降低血清抵抗素水平并显著提高脂联素水平,应加以推广。

Objective To investigate the efficacy of epirubicin combined with paclitaxel in the treatment of breast cancer and its influence on serum resistin and adiponectin levels.Methods A total of 96 patients with breast cancer diagnosed by pathology and imaging diagnosis were collected during January 2013-Januray 2016 and randomly divided into control group and observation group according to the ratio of 1 ∶1.The control group was treated with paclitaxel alone,and the observation group was treated with epirubicin combined with paclitaxel.The efficacy and serum resistin,adiponectin levels between the two groups were compared.Results The clinical total effective rate and clinical benefit rate of the control group were significantly higher than that of the control group,with the differences statistically significant（P〈0.05）;the endometrial thickness of the observation group for the treatment of half a year and 1 year were significantly less than the control group,with the difference statistically significant（P〈0.05）;after treatment,serum resistin levels of the two groups were significantly lower than that before treatment,serum adiponectin levels were significantly higher than those before treatment,with the differences statistically significant（P〈0.05）.Conclusion The combined treatment with epirubicin and paclitaxel is effective in the treatment of breast cancer.It can effectively reduce the serum resistin and improve the level of adiponectin,so it should be popularized.